Cantor Fitzgerald Begins Coverage on Replimune Group (NASDAQ:REPL)

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Replimune Group (NASDAQ:REPL) in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage set an “overweight” rating on the stock.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Piper Sandler increased their price objective on shares of Replimune Group from $14.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, June 2nd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $20.83.

Replimune Group Trading Down 2.3%

Shares of Replimune Group stock opened at $9.27 on Friday. Replimune Group has a 52-week low of $6.44 and a 52-week high of $17.00. The stock’s 50-day simple moving average is $8.83 and its 200 day simple moving average is $10.77. The stock has a market capitalization of $714.62 million, a P/E ratio of -3.02 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the company posted ($0.25) EPS. As a group, research analysts anticipate that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, CAO Andrew Schwendenman sold 3,287 shares of the firm’s stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the completion of the transaction, the chief accounting officer now directly owns 68,284 shares of the company’s stock, valued at approximately $549,686.20. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Konstantinos Xynos sold 7,952 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the sale, the insider now owns 146,933 shares of the company’s stock, valued at approximately $1,184,279.98. This represents a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock valued at $603,655 in the last three months. 8.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Replimune Group

A number of institutional investors have recently bought and sold shares of REPL. Sterling Capital Management LLC lifted its position in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after purchasing an additional 1,655 shares during the last quarter. Graham Capital Management L.P. raised its holdings in shares of Replimune Group by 6.1% in the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock valued at $365,000 after acquiring an additional 1,731 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Replimune Group by 0.4% in the first quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock valued at $5,496,000 after acquiring an additional 2,140 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock valued at $456,000 after acquiring an additional 2,525 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Replimune Group by 19.7% in the first quarter. Arizona State Retirement System now owns 15,439 shares of the company’s stock valued at $151,000 after acquiring an additional 2,545 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.